A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD

Wang, Jian; Huang, Rui; Liu, Jiacheng; Lai, Ruimin; Liu, Yilin; Zhu, Chengliang; Qiu, Yuanwang; He, Zhisong; Yin, Shengxia; Chen, Yuxin; Yan, Xiaomin; Ding, Weimao; Zheng, Qi; Li, Jie; Wu, Chao

doi:10.1111/jvh.13808

Cited by 4 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnostic efficacy was higher than that in our CHB & MASLD group but similar to our results in the CHB & MetALD group, and the cutoff values were higher than those in our CHB and SLD groups 26 . Wang et al 27 demonstrated that the AUC of FIB‐4 was 0.716 (0.656–0.775) when diagnosing ≥F3 fibrosis in patients with CHB & NAFLD (optimal cutoff: 1.343), which was lower than that in this study (0.774 [0.742–0.804]) (optimal cutoff: 1.414). A study by Ratziu et al between NAFLD and MASLD showed that the diagnostic accuracy of FIB‐4 and LSM in evaluating advanced fibrosis in NAFLD and MASLD was almost the same 28 .…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease

Chen,

Tao,

Zeng

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a new nomenclature proposed in 2023. We aimed to compare the diagnostic efficacy of noninvasive tests (NITs) for advanced fibrosis under different nomenclatures in patients with chronic hepatitis B (CHB). A total of 844 patients diagnosed with CHB and concurrent steatotic liver disease (SLD) by liver biopsy were retrospectively enrolled and divided into four groups. The performances of fibrosis‐4 (FIB‐4), gamma‐glutamyl transpeptidase to platelet ratio index (GPRI), aspartate aminotransferase to platelet ratio index (APRI), and liver stiffness measurement (LSM) were compared among the four groups. The four NITs showed similar diagnostic efficacy for nonalcoholic fatty liver disease (NAFLD), MASLD, and metabolic dysfunction‐associated fatty liver disease (MAFLD) in patients with CHB with advanced fibrosis. LSM showed the most stable accuracy for NAFLD (AUC = 0.842), MASLD (AUC = 0.846), and MAFLD (AUC = 0.863) compared with other NITs (p < 0.05). Among the four NITs, APRI (AUC = 0.841) and GPRI (AUC = 0.844) performed best in patients with CHB & MetALD (p < 0.05). The cutoff value for GPRI in patients with CHB & MetALD was higher than that in the other three groups, while further comparisons of NITs at different fibrosis stages showed that the median GPRI of CHB & MetALD (1.113) at F3‐4 was higher than that in the CHB & MASLD group (0.508) (p < 0.05). Current NITs perform adequately in patients with CHB and SLD; however, alterations in cutoff values for CHB & MetALD need to be noted.

show abstract

Section: Discussionsupporting

confidence: 88%

“…MetALD group, and the cutoff values were higher than those in our CHB and SLD groups. 26 Wang et al 27 and NAFLD (AUC = 0.8). 33,34 However, the performance of LSM in…”

Section: Further Comparisons Of Cutoff Values In Each Groupmentioning

confidence: 98%

Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease

Chen,

Tao,

Zeng

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…An alternate method that has benefits including becoming kinder to the body, safer, and more economical is to use non-invasive diagnostics [ 51 , 52 ]. To forecast liver histological alterations and fibrosis in CHB patients, several non-invasive models were created utilising various indicators [ 53 ], [ 54 ], [ 55 ]. With no requirement for a liver biopsy, these models have demonstrated encouraging outcomes in precisely evaluating liver histology and forecasting the requirement for antiviral medication.…”

Section: Prognostic Markersmentioning

confidence: 99%

A critical review of diagnostic and prognostic markers of chronic hepatitis B infection

Hudu,

Shinkafi,

Jimoh

2024

Medical Review

View full text Add to dashboard Cite

A major worldwide health concern, chronic hepatitis B necessitates precise prognostic and diagnostic indicators for clinical guidance. This article highlights the clinical importance and current issues of the major markers used in both the detection and prognosis of chronic hepatitis B. An important indicator of an ongoing and persistent infection is the hepatitis B surface antigen. Hepatitis B virus DNA quantification monitoring aids in assessing viral load and hepatic cancer risk. While limited evidence of liver damage is provided by alanine aminotransferase levels, the hepatitis B core antibody verifies acute infection. Seroconversion to the hepatitis B e antibody is linked to a lower risk of disease development, and the hepatitis B e antigen status is a critical prognostic factor. Treatment choices are guided by a biopsy of the liver or minimally invasive liver fibrosis detection. Genotypes of the hepatitis B virus and host variables influence the prognosis by adding to the disease’s variability. Noninvasive techniques to evaluate the severity of the disease are provided by serum markers of fibrosis, such as the fibrosis score based on four criteria and the aspartate aminotransferase-to-platelet ratio index. The requirement for indicators that distinguish between distinct viral phases and increase specificity in evaluating liver damage is one of the challenges facing chronic hepatitis B research. Even though it is quite difficult to find reliable biomarkers for resistance especially when it comes to hepatocellular cancer risk estimation, there are advanced methods, which include imaging and omics that can help in improving the accuracy of the diagnostics and prognosis. Interventions early point that improve patient outcomes are made possible using diagnostics and prognostics as they are quite effective in managing the complicated landscape of chronic hepatitis B. Key in addressing these challenges today and improving the diagnostic and prognostic markers in the future, particularly those that would support the development of successful treatment plans for people living with chronic hepatitis B virus (HBV), are scientific research, technological advances and collaborations.

show abstract

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis

Liu,

Feng,

Chi

et al. 2024

Hepatol Int

View full text Add to dashboard Cite

Background This cross-sectional study aimed to investigate the impact of metabolic-associated diseases (MADs) on patients with autoimmune hepatitis (AIH). Methods The study analyzed the clinical characteristics of 283 AIH patients who underwent liver biopsy between January 2016 and February 2022 in Ruijin Hospital, Shanghai, China. Results Among the identified AIH patients (n = 283), 87.3%, 23.0%, or 43.1% had MADs, non-alcoholic fatty liver disease (NAFLD), or severe fibrosis, respectively. The proportion of diabetes mellitus (DM) was significantly higher in patients with severe liver fibrosis than in those with mild or moderate fibrosis in the AIH cohort (31.1% vs. 18.0%, p < 0.05). Fibrosis was also more severe in patients with NAFLD than in those without (53.8% vs. 39.9%, p < 0.05). Age, Plts, IgG and the presence with MADs were identified as independent predictors of the severity of inflammation in AIH patients. Moreover, severe liver fibrosis (stages 3 to 4) was independently associated with male (OR, 2.855; p = 0.025), γ-GT (OR, 0.997; p = 0.007), and combination with MADs (OR, 4.917; p = 0.006). Furthermore, combination with DM was also an independent predictor of severe liver fibrosis in AIH patients (OR, 2.445, p = 0.038). Conclusions Concurrent MADs, common in AIH patients, is an independent risk factor for severe fibrosis or inflammation; of note, combination with DM was also an independent predictor of severe liver fibrosis in AIH patients. While managing with AIH, routine assessment of co-existing MADs, especially DM, is also important.

show abstract

A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD

Cited by 4 publications

References 47 publications

Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease

Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease

A critical review of diagnostic and prognostic markers of chronic hepatitis B infection

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis

Contact Info

Product

Resources

About